Market revenue in 2023 | USD 15,453.2 million |
Market revenue in 2030 | USD 24,222.0 million |
Growth rate | 6.6% (CAGR from 2023 to 2030) |
Largest segment | Cmos & cdmos |
Fastest growing segment | CMOs & CDMOS |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biopharmaceutical Companies, CMOs & CDMOS, Academic And Research Organizations |
Key market players worldwide | Danone SA, Roche Holding AG ADR, Koninklijke DSM NV, Lonza Group Ltd, Novonesis AS ADR, Biocon, BioVectra, TerraVia - Assets, BiOZEEN |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to microbial fermentation technology market will help companies and investors design strategic landscapes.
Cmos & cdmos was the largest segment with a revenue share of 42.16% in 2023. Horizon Databook has segmented the Asia Pacific microbial fermentation technology market based on biopharmaceutical companies, cmos & cdmos, academic and research organizations covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific contributes to two-thirds of the world’s population, and certain countries in this region even have a large geriatric population. The region is anticipated to witness the largest and the fastest growth in bioprocessing industry in the coming years, which in turn is likely to increase the growth prospects for microbial fermentation technology market.
This can be attributed to factors such as the growing prevalence of chronic diseases, supportive government regulations, development of APAC economies, and increased domestic demand for biologics. The presence of several government initiatives for immunization has led APAC manufacturers to focus on vaccine development and facilitate faster market entry.
The faster market entry of biotherapeutics and vaccines by manufacturing entities is achieved by implementing microbial fermentation technology. Moreover, the cost-saving advantages of microbial fermentation complement the business dynamics of the region, which is primarily based on low operating and lower labor costs.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific microbial fermentation technology market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific microbial fermentation technology market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account